{"id":45255,"date":"2025-10-30T15:26:51","date_gmt":"2025-10-30T07:26:51","guid":{"rendered":"https:\/\/flcube.com\/?p=45255"},"modified":"2025-10-30T15:26:51","modified_gmt":"2025-10-30T07:26:51","slug":"biomarin-cuts-2027-revenue-target-amid-voxzogo-competition","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45255","title":{"rendered":"BioMarin Cuts 2027 Revenue Target Amid Voxzogo Competition"},"content":{"rendered":"\n<p><strong>BioMarin Pharmaceutical Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/BMRN:NASDAQ\">NASDAQ: BMRN<\/a>) announced during its third\u2011quarter earnings call that it no longer expects to hit its <strong>USD\u202f4\u202fbillion<\/strong> revenue target by 2027. The company cited slowing uptake of its gene\u2011therapy product <strong>Roctavian<\/strong> and the looming entry of competitors for its achondroplasia therapy <strong>Voxzogo<\/strong> as the primary drivers of the revised outlook.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-roctavian-divestment-and-sales-slump\"><strong>Roctavian Divestment and Sales Slump<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Product Background<\/strong> \u2013 Roctavian, an AAV5\u2011vector\u2011based gene therapy approved by the FDA in June\u202f2023, delivers a functional copy of the Factor\u202fVIII gene to achieve a one\u2011time cure for hemophilia\u202fA.<\/li>\n\n\n\n<li><strong>Market Performance<\/strong> \u2013 The therapy generated <strong>USD\u202f26\u202fmillion<\/strong> in revenue in 2024, far below expectations. In August\u202f2024, BioMarin scaled back commercialization to the U.S., Germany, and Italy, laid off ~225 employees, and shut its gene\u2011therapy manufacturing site.<\/li>\n\n\n\n<li><strong>Cost Reduction Plan<\/strong> \u2013 Annual direct spending on Roctavian is being trimmed to ~USD\u202f60\u202fmillion, and new patient enrollment for clinical trials has been halted. The company is now preparing to divest the product line.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-voxzogo-faces-growing-competition\"><strong>Voxzogo Faces Growing Competition<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current Position<\/strong> \u2013 Voxzogo, a subcutaneous CNP analog for achondroplasia, grew 15\u202f% YoY in Q3, adding <strong>USD\u202f218\u202fmillion<\/strong>\u2014nearly one\u2011third of BioMarin\u2019s <strong>USD\u202f776\u202fmillion<\/strong> total revenue.<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong> \u2013 Two challengers, <strong>Ascendis Pharma<\/strong> and <strong>BridgeBio<\/strong>, are rapidly developing alternative therapies, threatening Voxzogo\u2019s monopoly on the most common form of dwarfism.<\/li>\n\n\n\n<li><strong>Revenue Forecast<\/strong> \u2013 Executives \u201cinformally\u201d indicated that 2027 revenue could fall between <strong>USD\u202f3.65\u202fbillion<\/strong> and <strong>USD\u202f4\u202fbillion<\/strong>, reflecting the potential erosion of Voxzogo\u2019s market share.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-outlook\"><strong>Strategic Outlook<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>BioMarin is reassessing its portfolio, prioritizing high\u2011margin projects and exploring divestiture of low\u2011performing assets.<\/li>\n\n\n\n<li>The company remains focused on accelerating other gene\u2011therapy candidates and expanding access to existing products in under\u2011served markets.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced during its third\u2011quarter earnings call that it no longer&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45257,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[2752,1132],"class_list":["post-45255","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-biomarin-pharmaceutical","tag-nasdaq-bmrn"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BioMarin Cuts 2027 Revenue Target Amid Voxzogo Competition - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced during its third\u2011quarter earnings call that it no longer expects to hit its USD\u202f4\u202fbillion revenue target by 2027. The company cited slowing uptake of its gene\u2011therapy product Roctavian and the looming entry of competitors for its achondroplasia therapy Voxzogo as the primary drivers of the revised outlook.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45255\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioMarin Cuts 2027 Revenue Target Amid Voxzogo Competition\" \/>\n<meta property=\"og:description\" content=\"BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced during its third\u2011quarter earnings call that it no longer expects to hit its USD\u202f4\u202fbillion revenue target by 2027. The company cited slowing uptake of its gene\u2011therapy product Roctavian and the looming entry of competitors for its achondroplasia therapy Voxzogo as the primary drivers of the revised outlook.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45255\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-30T07:26:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3001.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45255#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45255\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BioMarin Cuts 2027 Revenue Target Amid Voxzogo Competition\",\"datePublished\":\"2025-10-30T07:26:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45255\"},\"wordCount\":309,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45255#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3001.webp\",\"keywords\":[\"BioMarin Pharmaceutical\",\"NASDAQ: BMRN\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45255#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45255\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45255\",\"name\":\"BioMarin Cuts 2027 Revenue Target Amid Voxzogo Competition - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45255#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45255#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3001.webp\",\"datePublished\":\"2025-10-30T07:26:51+00:00\",\"description\":\"BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced during its third\u2011quarter earnings call that it no longer expects to hit its USD\u202f4\u202fbillion revenue target by 2027. The company cited slowing uptake of its gene\u2011therapy product Roctavian and the looming entry of competitors for its achondroplasia therapy Voxzogo as the primary drivers of the revised outlook.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45255#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45255\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45255#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3001.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3001.webp\",\"width\":1080,\"height\":608,\"caption\":\"BioMarin Cuts 2027 Revenue Target Amid Voxzogo Competition\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45255#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioMarin Cuts 2027 Revenue Target Amid Voxzogo Competition\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BioMarin Cuts 2027 Revenue Target Amid Voxzogo Competition - Insight, China&#039;s Pharmaceutical Industry","description":"BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced during its third\u2011quarter earnings call that it no longer expects to hit its USD\u202f4\u202fbillion revenue target by 2027. The company cited slowing uptake of its gene\u2011therapy product Roctavian and the looming entry of competitors for its achondroplasia therapy Voxzogo as the primary drivers of the revised outlook.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45255","og_locale":"en_US","og_type":"article","og_title":"BioMarin Cuts 2027 Revenue Target Amid Voxzogo Competition","og_description":"BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced during its third\u2011quarter earnings call that it no longer expects to hit its USD\u202f4\u202fbillion revenue target by 2027. The company cited slowing uptake of its gene\u2011therapy product Roctavian and the looming entry of competitors for its achondroplasia therapy Voxzogo as the primary drivers of the revised outlook.","og_url":"https:\/\/flcube.com\/?p=45255","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-30T07:26:51+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3001.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45255#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45255"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BioMarin Cuts 2027 Revenue Target Amid Voxzogo Competition","datePublished":"2025-10-30T07:26:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45255"},"wordCount":309,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45255#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3001.webp","keywords":["BioMarin Pharmaceutical","NASDAQ: BMRN"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45255#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45255","url":"https:\/\/flcube.com\/?p=45255","name":"BioMarin Cuts 2027 Revenue Target Amid Voxzogo Competition - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45255#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45255#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3001.webp","datePublished":"2025-10-30T07:26:51+00:00","description":"BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced during its third\u2011quarter earnings call that it no longer expects to hit its USD\u202f4\u202fbillion revenue target by 2027. The company cited slowing uptake of its gene\u2011therapy product Roctavian and the looming entry of competitors for its achondroplasia therapy Voxzogo as the primary drivers of the revised outlook.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45255#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45255"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45255#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3001.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3001.webp","width":1080,"height":608,"caption":"BioMarin Cuts 2027 Revenue Target Amid Voxzogo Competition"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45255#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BioMarin Cuts 2027 Revenue Target Amid Voxzogo Competition"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3001.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45255","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45255"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45255\/revisions"}],"predecessor-version":[{"id":45258,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45255\/revisions\/45258"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45257"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45255"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45255"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}